Avantor, Inc. Stock 12‑Month Price Target Raised to $15.96, Implies 7% Downside

Avantor, Inc.'s average stock price target increased to $15.96 from $15.5, with estimates ranging from $13 to $19. This implies a 7% downside based on the Oct. 27 closing price. The consensus rating remains 'Hold' among 18 analysts.

Original reporting
Published Oct 28, 2026, 7:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 7:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Avantor, Inc. Stock 12‑Month Price Target Raised to $15.96, Implies 7% Downside — source image
Decision brief

The 30-second read

$AVTRNeutralLow
01

Why it matters

Analyst price target adjustments can influence short-term trading sentiment but are unlikely to drive large price moves without additional catalysts.

02

Market read

The price target update offers modest insight for traders but lacks a strong actionable catalyst.

03

What to watch

Potential upcoming product launches or contract wins not reflected in the current analyst consensus.

Relevance 5/10Novelty 5/10Timing: today

Background

Avantor is a global provider of chemicals and services to the life sciences and advanced technologies markets.

Company-level read

Ticker impact

$AVTRNeutralMedium confidence
Context

Analyst consensus price target raised to $15.96, implying ~7% downside from the current price.

Expected impact

potential downside pressure as the market prices in the lower upside potential

Evidence & confidence

Price target change is small and the consensus rating remains Hold, indicating no strong catalyst for a move.

Market effects

Minor impact on specialty chemicals sector as analysts adjust expectations for Avantor.

Limited to US-listed specialty chemicals investors.

Low global relevance.

Counterpoint

Investors may view the target raise as a sign of underlying strength despite the implied downside.

Key entities

  • Avantor, Inc.

    Specialty chemicals and life sciences services provider.

Related articles

$AVTRMedAI 8/10

Avantor Inc (AVTR) Q3 2026 Earnings Call Highlights: Return to Organic Growth, Raised

Avantor Inc (AVTR) reported Q3 2026 earnings, highlighting organic growth and raised guidance. CEO Emmanuel Ligner expressed confidence in 2027, citing strong momentum. CFO Todd Garner forecasted Q4 revenue growth of 2.5% to 4.5%, with VWR growing mid-single-digits. AI is seen as a potential tailwind. Margins faced pressure from mix and inflation, but EBITDA margin expansion is expected to continue. Investments in facilities and AI tools are ongoing, with returns anticipated over time.

$AVTRHighAI 8/10

What Avantor (AVTR) Said on Its Q3 Earnings Call

Avantor (AVTR) reported Q3 revenue of $465M for its Bioscience & Medtech Products segment, up 3.6% organically. Adjusted operating income was $123M with a 26.6% margin. The company raised its 2026 organic revenue growth outlook to 0.75-1.25% and increased its adjusted EPS and free cash flow projections. Avantor aims to reduce net leverage below 3x by year-end.

$AVTRHighAI 8/10

Avantor (AVTR) Q3 2026 Earnings Call Transcript

Avantor (AVTR) reported Q3 2026 earnings, exceeding expectations with $1.698B revenue (5.2% organic growth) and $0.22 adjusted EPS. VWR and BMP segments showed strong performance, driving growth. The company raised full-year guidance and aims to reduce leverage below 3x by year-end. Revival initiatives are improving execution and end-market demand.